Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial. Issue 3 (23rd February 2022)

Record Type:: Journal Article
Title:: Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial. Issue 3 (23rd February 2022)
Main Title:: Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial
Authors:: Zeidan, Amer M.
Qi, Cynthia Z.
Yang, Hongbo
Garnham, Andy
Shah, Manasee V.
Pandya, Bhavik J.
Abstract:
Is Part Of:: Leukemia & lymphoma. Volume 63:Issue 3(2022)
Journal:: Leukemia & lymphoma
Issue:: Volume 63:Issue 3(2022)
Issue Display:: Volume 63, Issue 3 (2022)
Year:: 2022
Volume:: 63
Issue:: 3
Issue Sort Value:: 2022-0063-0003-0000
Page Start:: 762
Page End:: 764
Publication Date:: 2022-02-23
Subjects:: Leukemia -- Periodicals
Lymphomas -- Periodicals
616.99419
Journal URLs:: http://informahealthcare.com ↗
DOI:: 10.1080/10428194.2021.2001467 ↗
Languages:: English
ISSNs:: 1042-8194
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 5185.251500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 21446.xml